Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alpheus Medical

Request full access

A privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers

Chanhassen, United StatesHealth

About Alpheus Medical

Alpheus Medical, Inc. is a privately held, clinical-stage oncology company founded in 2020 by Dr. Vijay Agarwal. Dr. Agarwal, a practicing brain tumor surgeon with a background in electrical and biomedical engineering, established the firm to address the significant challenges in treating aggressive solid tumors. His career, including a neurosurgery residency at Duke University and over two decades in the medical device and biotechnology industry, has been dedicated to improving outcomes for brain cancer patients.

The company is developing a non-invasive sonodynamic therapy (SDT) platform to treat solid body cancers, with a primary focus on glioblastoma (GBM), the most aggressive form of primary brain cancer. Alpheus Medical's business model centers on the development and commercialization of its proprietary drug-device combination therapy. The treatment is designed for an outpatient setting, which could significantly improve the quality of life for patients. The company's target market consists of patients with difficult-to-treat solid tumors, particularly those with newly diagnosed or recurrent glioblastoma.

Alpheus Medical's core product is a sonodynamic therapy that combines an orally administered, FDA-approved drug called 5-aminolevulinic acid (5-ALA) with the company's proprietary low-intensity diffuse ultrasound (LIDU™) device. The process begins with the patient ingesting 5-ALA, which selectively accumulates in cancer cells. Subsequently, the non-invasive device applies ultrasound to the entire brain hemisphere, which activates the drug. This activation causes the release of reactive oxygen species, a form of oxygen that destroys the targeted cancer cells while sparing healthy tissue. A key benefit of this approach is its ability to treat the entire hemisphere without requiring imaging or sedation during the procedure.

The company has achieved significant milestones, including receiving both Orphan Drug and Fast Track designations from the U.S. FDA in July 2022 for its treatment of recurrent glioblastoma. Alpheus has progressed through multiple funding rounds, securing a $16 million Series A in November 2021 and an oversubscribed $52 million Series B in May 2025. These funds are supporting a Phase 2B randomized controlled trial for newly diagnosed GBM. Early clinical trials have shown promising results, with data indicating a doubling of median overall survival and a threefold improvement in progression-free survival for patients with recurrent high-grade gliomas compared to historical averages. The company collaborates with leading neuro-oncology experts and is backed by prominent investors, including the American Cancer Society and the National Brain Tumor Society.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Industry
Health
Sector
Hard Tech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2025 $52M $208M Sontag foundation · Brain Tumor Investment Fund · Samsara BioCapital · OrbiMed ↗
SERIES AOther financing Nov 2022 $14M $80M OrbiMed · Action Potential Venture Capital · SV Health Investors · BrightEdge ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Alpheus Medical website traffic

Latest recorded traffic for Alpheus Medical is 1.5K monthly website visits, down 16.7% over the last three months. Alpheus Medical's team grew 22.2% over the past year.

Latest monthly visits1.5K 3-month web change-16.7% 1-year team growth+22.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alpheus Medical in the Chanhassen ecosystem

Live from Dealroom

The Alpheus Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • OrbiMed
  • Action Potential Venture Capital
  • BrightEdge
  • SV Health Investors
  • Brain Tumor Society
  • Samsara BioCapital
  • HealthQuest Capital
  • Sontag foundation
  • Brain Tumor Investment Fund
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alpheus Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alpheus Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.